Flutiform (Asthma) – Forecast and Market Analysis to 2023: Order report by calling marketoptimizer.org at +1 888 391 5441 OR send an email on sales@marketoptimizer.org with Flutiform (Asthma) – Forecast and Market Analysis to 2023 in subject line and your contact details. PharmaPoint Drug Evaluation report, “Flutiform (Asthma) – Forecast and Market Analysis to 2023″. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline. SkyePharma’s Flutiform is an FDC of fluticasone propionate and formoterol fumarate. Fluticasone propionate is a synthetic corticosteroid with strong anti-inflammatory activity. Fluticasone can bind to glucocorticoid receptors with high affinity and inhibit the secretion of mediators involved in asthma, such as histamine, eicosanoids, leukotrienes, and cytokines. It is three times more potent than budesonide and two times more potent than the active metabolite of beclomethasone dipropionate. Formoterol fumarate is a LABA that exerts its bronchodilatory activity locally in the lung. LABAs act by stimulating intracellular adenylate cyclase, resulting in increased cAMP levels, which, in turn, cause relaxation of bronchial smooth muscle, inhibiting the release of hypersensitivity mediators, such as histamine and leukotrienes, from cells, especially mast cells. Complete report available at http://www.marketoptimizer.org/flutiform-asthma-forecast-and-marketanalysis-to-2023.html . Scope
Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on Flutiform including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Flutiform for the top seven countries from 2013 to 2023. Sales information covered for France, Germany, Italy, Spain, the UK, Japan and Australia.
Reasons to Buy
Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Asthma Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of Flutiform performance Obtain sales forecast for Flutiform from 2013-2023 in top seven countries (France, Germany, Italy, Spain, the UK, Japan and Australia)
Inquire for discount @ http://www.marketoptimizer.org/contacts/discount?rname=10546 (Report price: Single user license- US$ 3495 ) Table of Contents Table of Contents 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Catalyst 2.2 Related Reports 2.3 Upcoming Related Reports 3 Disease Overview 3.1 Etiology and Pathophysiology 3.1.1 Etiology 3.1.2 Pathophysiology 3.1.3 Prognosis 3.1.4 Quality of Life 3.2 Symptoms 4 Disease Management 4.1 Diagnosis and Treatment Overview
Buy a Copy of the Report @ http://www.marketoptimizer.org/contacts/purchase?rname=10546 . Table of Contents 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitor Assessment 6 Flutiform (fluticasone propionate/formoterol fumarate) 6.1 Overview
6.2 Efficacy 6.3 Safety 6.4 SWOT Analysis 6.5 Forecast 7 Appendix 7.1 Bibliography 7.2 Abbreviations 7.3 Methodology 7.4 Forecasting Methodology 7.4.1 Diagnosed Asthma Patients 7.4.2 Percent Drug-Treated Patients
Contact sales@marketoptimizer.org / Call +1 888 391 5441 for further information on “Flutiform (Asthma) – Forecast and Market Analysis to 2023” report OR for any other market research and intelligence needs you may have for your business.